Urologic CA Predictors ID'd in Women With Microhematuria

Share this content:
Urologic CA Predictors ID'd in Women With Microhematuria
Urologic CA Predictors ID'd in Women With Microhematuria

TUESDAY, Feb. 7, 2017 (HealthDay News) -- Older age, history of smoking, and gross hematuria predict urologic cancer in women with microscopic hematuria, according to a study published in the February issue of the American Journal of Obstetrics & Gynecology.

Quinn K. Lippmann, M.D., M.P.H., from San Diego Medical Center, and colleagues examined risk factors associated with urologic cancer in women with microscopic hematuria in a retrospective cohort study. All urinalyses with microscopic hematuria that were performed from 2009 to 2015 were identified. A total of 14,539 women were referred for urologic evaluation; clinical data were obtained for 3,573 women.

The researchers found that the overall rate of urologic cancer was 1.3 percent; the rate was 0.6 and 2.2 percent in women aged <60 years versus those aged ≥60 years. The rate of urologic cancer was 5.8 percent in women who reported a history of gross hematuria versus 0.8 percent in those with no history of gross hematuria. Age >60 years, history of smoking, and history of gross hematuria in the past six months correlated with urologic cancer in multivariate analysis (odds ratios, 3.1, 3.2, and 6.2, respectively). Higher microscopic hematuria risk score correlated with increased risk of cancer. The rate of urologic cancer was 10.8 versus 0.5 percent for women in the highest- versus the lowest-risk group.

"In this female population, >60 years old and a history of smoking and/or gross hematuria were the strongest predictors of urologic cancer," the authors write.

Two authors disclosed financial ties to UpToDate.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »